FENTANYL REMAINING IN A TRANSDERMAL SYSTEM FOLLOWING 3 DAYS OF CONTINUOUS USE

被引:69
作者
MARQUARDT, KA [1 ]
THARRATT, RS [1 ]
MUSALLAM, NA [1 ]
机构
[1] UNIV CALIF SAN FRANCISCO,SCH PHARM,SAN FRANCISCO,CA
关键词
D O I
10.1177/106002809502901001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO determine whether there was a sufficient amount of fentanyl remaining in a patch that had been used continuously for 3 days to warrant establishment of disposal policies to prevent diversion of fentanyl. DESIGN: Nine patches were applied and removed by hospice nurses after 3 days of continuous use on hospice patients with cancer. Patches were analyzed for the remaining fentanyl contents using the Coat-A-Count Fentanyl radioimmunoassay. Five 2.5-mg patches and four 10.0-mg patches were opened, solubilized with methanol, diluted with water, and analyzed in duplicate. An unused 2.5-mg patch also was analyzed as a control and showed a 94% recovery of fentanyl. A methanol blank was negative for fentanyl. MAIN OUTCOME MEASURES: The study determined the amount of fentanyl in milligrams remaining in a used patch. Using pharmacokinetic principles, this quantity was compared with a potential lethal dose of fentanyl. RESULTS: Analysis showed 0.7-1.22 mg remaining in the 2.5-mg patches and 4.46-8.44 mg remaining in the 10.0-mg patches. These numbers represent 28-84.4% of the original contents. Using the pharmacokinetic values of the volume of distribution of 4 L/kg and a potential lethal blood concentration of 3.7 mu g/L, one can calculate the potential lethal dose for a 70-kg person to be 1036 mu g. This is well within the amount remaining in the patch. This study also demonstrated that a wide patient variability exists in the absorption of fentanyl from the patch. CONCLUSIONS: There is a sufficient amount of fentanyl available for abuse and misuse after 3 days of therapeutic use. Adequate disposal policies currently are not established and need to be implemented.
引用
收藏
页码:969 / 971
页数:3
相关论文
共 11 条
  • [1] BASELT RC, 1989, DISPOSITION TOXIC DR, P351
  • [2] INTRAVENOUS ABUSE OF TRANSDERMAL FENTANYL THERAPY IN A CHRONIC PAIN PATIENT
    DESIO, JM
    BACON, DR
    PEER, G
    LEMA, MJ
    [J]. ANESTHESIOLOGY, 1993, 79 (05) : 1139 - 1141
  • [3] INHALATION ABUSE OF FENTANYL PATCH
    MARQUARDT, KA
    THARRATT, RS
    [J]. JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1994, 32 (01): : 75 - 78
  • [4] MCEVOY GK, 1992, ASHP DRUG INFORMATIO, P1135
  • [5] SENSITIVE RADIOIMMUNOASSAY FOR FENTANYL - PLASMA-LEVEL IN DOGS AND MAN
    MICHIELS, M
    HENDRIKS, R
    HEYKANTS, J
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 12 (02) : 153 - 158
  • [6] TRANSDERMAL FENTANYL FOR CANCER PAIN - REPEATED DOSE PHARMACOKINETICS
    PORTENOY, RK
    SOUTHAM, MA
    GUPTA, SK
    LAPIN, J
    LAYMAN, M
    INTURRISI, CE
    FOLEY, KM
    [J]. ANESTHESIOLOGY, 1993, 78 (01) : 36 - 43
  • [7] FENTANYL TRANSDERMAL SYSTEM OVERDOSE SECONDARY TO CUTANEOUS HYPERTHERMIA
    ROSE, PG
    MACFEE, MS
    BOSWELL, MV
    [J]. ANESTHESIA AND ANALGESIA, 1993, 77 (02) : 390 - 391
  • [8] ABSORPTION CHARACTERISTICS OF TRANSDERMALLY ADMINISTERED FENTANYL
    VARVEL, JR
    SHAFER, SL
    HWANG, SS
    COEN, PA
    STANSKI, DR
    [J]. ANESTHESIOLOGY, 1989, 70 (06) : 928 - 934
  • [9] EVALUATION OF THE COAT-A-COUNT I-125 FENTANYL RIA - COMPARISON OF I-125 RIA AND GC/MS-SIM FOR QUANTIFICATION OF FENTANYL IN CASE URINE SPECIMENS
    WATTS, VW
    CAPLAN, YH
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 1990, 14 (05) : 266 - 272
  • [10] ASSAY-METHODS FOR FENTANYL IN SERUM - GAS-LIQUID-CHROMATOGRAPHY VERSUS RADIOIMMUNOASSAY
    WOESTENBORGHS, RJH
    STANSKI, DR
    SCOTT, JC
    HEYKANTS, JJP
    [J]. ANESTHESIOLOGY, 1987, 67 (01) : 85 - 90